Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Chenodeoxycholic Acid: From FXR Signal to Assay Design
2026-08-17
Chenodeoxycholic Acid (CDCA) is more than an FXR agonist: it can serve as a mechanistic probe linking bile acid metabolism to transcriptional and injury-response assays. This guide translates recent FXR–KLF11 findings into a rigorous framework for experimental design, controls, and interpretation.
-
Central Control of Opioid Mechanical Hypersensitivity
2026-08-17
Yin et al. identify a brain-to-spinal opioid pathway linking MOR-expressing neurons in the lateral parabrachial nucleus, dynorphin neurons in the hypothalamus, and KOR-expressing GABAergic neurons in the spinal dorsal horn. Their findings distinguish central control of mechanical opioid-induced hypersensitivity and tolerance from better-established thermal mechanisms and provide a circuit framework for receptor- and pathway-level experiments.
-
ETS1–SENP2 Axis in Bronchopulmonary Dysplasia
2026-08-16
A 2026 study identifies ETS1 as a transcriptional regulator that protects against hyperoxia-associated bronchopulmonary dysplasia by coordinating SENP2-dependent deSUMOylation, HSPA8 binding, and FUNDC1 degradation. The findings connect mitochondrial quality control with alveolar injury and suggest that excessive mitophagy, rather than autophagy activation in general, may be a context-dependent therapeutic target.
-
Plant Cell Lysis Buffer for WB and IP: MAPK10 Assays
2026-08-15
Build cleaner Western blotting, immunoprecipitation, and co-IP workflows from plant, animal, fungal, or bacterial samples with a non-denaturing extraction system. This guide translates MAPK10–KRT16 pathway findings into practical sample-preparation, assay-selection, and troubleshooting decisions.
-
hCG, H3K27 Methylation, and CXCL10 in Decidua
2026-08-14
The reference study identifies a hormone–chromatin–chemokine pathway in which trophoblast-derived hCG increases EZH2-associated H3K27me3 at the CXCL10 promoter in human decidual stromal cells. This mechanism links placental signaling to reduced CD8 T-cell recruitment and provides a useful framework for studying epigenetic control of immune adaptation at the maternal–fetal interface.
-
T7 RNA Polymerase for Precise In Vitro RNA Synthesis
2026-08-14
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes DNA templates carrying a T7 promoter. Its defined promoter recognition supports in vitro RNA synthesis for research workflows, including RNA vaccine production, antisense RNA, and RNAi studies.
-
Bestatin (Ubenimex): Mechanism & Research Guide
2026-08-13
Bestatin, also called Ubenimex, is a research aminopeptidase inhibitor with reported activity against cytosol aminopeptidase, aminopeptidase N, zinc aminopeptidase, and aminopeptidase B. Its effects are assay-dependent: a peer-reviewed fibrin-matrix model found enhanced endothelial tube formation, so Bestatin should not be labeled universally anti-angiogenic.
-
Optimized GBA1 mRNA for Gaucher Disease Therapy
2026-08-13
The reference study develops a rationally optimized human GBA1 mRNA platform that improves glucocerebrosidase expression, durability, and lysosomal delivery. In cellular and mouse experiments, the mRNA–lipid nanoparticle system restored disease-relevant enzyme function, supporting further investigation of mRNA therapy as an alternative or complement to enzyme replacement and substrate reduction strategies.
-
PNU 74654: Designing Better Wnt Assays
2026-08-12
PNU 74654 is a Wnt signaling pathway inhibitor for testing how β-catenin-dependent signals shape cell fate. This guide focuses on causal assay design, controls, and responsible interpretation across cancer research, stem cell research, and muscle biology.
-
Praeruptorin A, DMT1, and Ferroptosis in DIC
2026-08-12
This study used a ferrous-ion probe to screen herbal small molecules and identified Praeruptorin A as an intervention candidate for doxorubicin-induced cardiomyopathy. The evidence connects Praeruptorin A with reduced DMT1 expression, lower cardiomyocyte Fe2+ overload, suppressed ferroptosis, improved cardiac function, and retained doxorubicin antitumor activity.
-
ABT-263 (Navitoclax) Apoptosis Workflow
2026-08-11
Build more informative apoptosis assays with ABT-263 (Navitoclax), from dose-response screening to mitochondrial mechanism validation. This workflow also translates a senescence-selective study into practical controls without overstating what Navitoclax has demonstrated in non-cancer tissues.
-
CD28–ARS2–PKM2 Axis in CD8+ T Cells
2026-08-11
Holling and colleagues identify a CD28–ARS2 signaling axis that reshapes alternative splicing of PKM in activated CD8+ T cells, favoring PKM2 over PKM1. The work connects costimulation, RNA processing, glucose-use flexibility, interferon-γ production, and antitumor effector activity through a mechanism that is distinct from canonical CD28–PI3K signaling.
-
Cardiogreen: From Vascular Imaging to PDT
2026-08-10
Cardiogreen, also known as Indocyanine green, connects vascular diagnostics with near-infrared therapeutic research. This guide translates its optical properties into practical workflows for cardiac output measurement, liver blood flow assessment, ophthalmic angiography, and photothermal or photodynamic assays in cancer models.
-
U0126-EtOH: MEK1/2 Inhibitor Workflows
2026-08-09
U0126-EtOH provides a practical way to interrogate MEK1/2-dependent ERK signaling across neuronal, inflammatory, and leukemia models. This guide translates pathway selectivity into executable workflows, assay controls, and troubleshooting decisions for oxidative stress research and mechanistic cell biology.
-
Hexa-Acylated LPS and Cancer Immunotherapy Response
2026-08-08
A 2025 Nature Microbiology study identifies the structure of gut microbiota-derived lipopolysaccharide, rather than bacterial taxonomy alone, as a functional determinant of anti-PD-1 response. Patient metagenomics, immune assays, and mouse tumor experiments show that hexa-acylated LPS activates TLR4-dependent immunity and can enhance checkpoint blockade efficacy.